R-CHOP Vs DA-EPOCH-R for Double-Expressor Lymphoma: A University of California Hematologic Malignancies Consortium Retrospective Analysis

By rosaguerrero • July 21, 2022

Othman T, Penaloza J, Zhang S, Daniel CE, Gaut D, Oliai C, Brem EA, Baweja A, Ly J, Reid J, Pinter-Brown L, Lee M, Abdulhaq H, Tuscano J. R-CHOP Vs DA-EPOCH-R for Double-Expressor Lymphoma: A University of California Hematologic Malignancies Consortium Retrospective Analysis. Clin Lymphoma Myeloma Leuk. 2022 Jun 30:S2152-2650(22)00217-8. doi: 10.1016/j.clml.2022.06.013. Epub ahead of print. PMID: 35858904.

Tags: DA-EPOCH-R, Diffuse large B-cell lymphoma, DLBCL, Double-expressor lymphoma, Hematology/Oncology, R-CHOP

Patient, care partner, and provider voice in treatment decision-making for non-small cell lung cancer

Orr LD, Vanderpoel J, Vadagam P, Patel MI, Roy UB, Ledezma B, Yung M, Deering KL, Kulbokas V, Feldman J, Gray JE. Patient, care partner,[...]

Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1/2 and phase 2 trials

Zhao S, Cheng Y, Wang Q, Li X, Liao J, Rodon J, Meng X, Luo Y, Chen Z, Wang W, Yi T, Li Y, Yin[...]

Body mass index as a predictive factor for efficacy of adjuvant taxane-based chemotherapy in early-stage breast cancer patients: A pooled analysis from adjuvant GEICAM Spanish Breast Cancer Group and TRIO Translational Research in Oncology Group studies

García-Saenz JA, Spera G, Pollán M, Bermejo B, Ruiz-Borrego M, Chan A, Martín M, Guerrero-Zotano Á, Calvo L, Rodríguez-Lescure Á, Marín M, Chap L, Crown[...]